Protein chemistry & metabolism

Our research is concerned with the control of the body’s energy metabolism via an enzyme called AMP-activated protein kinase (AMPK). This enzyme acts as the body’s fuel gauge, determining its energy level and is at the hub of metabolic control in response to diet and exercise.

Research Overview

It is well recognized that diet and sedentary life-styles are major contributors to obesity and cardiovascular disease and regular exercise together with moderate caloric intake are important for maintaining health. For example AMPK controls the synthesis of fats including, triglycerides and cholesterol and is responsible for burning fat in response to exercise.

In the brain AMPK is involved in appetite control. All the body’s functions depend on energy and research on AMPK is likely to greatly increase our understanding of the interrelationships between physiological functions, caloric intake, energy metabolism and exercise. We need to understand the molecular details of how the AMPK is regulated.

In an era of epidemic obesity, diabetes and sedentary lifestyles this research has the potential to provide new therapeutic developments and, even more importantly, new insights for the molecular basis of age onset diseases particularly, obesity, diabetes and cardiovascular disease. We use techniques such as protein chemistry, molecular biology, protein crystallography, mass spectrometry, gene knock out and knock in mouse models to study AMPK.

Team leaders

Prof Bruce E. Kemp, Head, Protein Chemistry & Metabolism Unit 
Dr Sandra Galic, Metabolic Physiology Team Leader

Research Themes

Control of AMPK signalling by adenylate charge

AMP-activated protein kinase (AMPK), is an αβγ heterotrimeric serine/threonine kinase that is directly responsible for sensing cellular metabolic stress. Under conditions of energy deprivation (low glucose) or high-energy demand (vigorous exercise) cellular adenylate charge ([ATP + 0.5 ADP]/[ATP = + ADP + AMP]) is reduced ie levels of ATP decrease and ADP, AMP levels rise and this switches on AMPK. The AMPK catalytic subunit contains an N-terminal kinase domain and a C-terminal subunit-binding domain that associates with the subunit’s C-terminal tail. The subunit consists of four CBS repeat sequences of which sites 1, 3 and 4 are responsible for binding adenine nucleotides. AMPK is inactive unless phosphorylated on T172 in the subunit activation loop by upstream kinases (eg LKB1, CaMKK). We have found that AMP binding to the subunit sites 1 and 3 stimulates phosphorylation of T172 by LKB1 and CaMKK. Stimulation of T172 phosphorylation depends on the N-terminal myristoylation of the subunit so that AMP fails to stimulate AMPK T172 phosphorylation if the subunit is non-myristoylated.  These finding indicate that AMP stimulation of T172 phosphorylation may involve a “myristoyl switch” mechanism whereby AMP triggers the release of the myristoyl group.. AMP has two additional regulatory functions once AMPK is phosphorylated on T172 but these secondary regulatory effects do not require subunit myristoylation. AMP suppresses the dephosphorylation of T172 by protein phosphatases as well as stimulating AMPK activity allosterically.  ADP also stimulates T172 phosphorylation and suppresses dephosphorylation but does not act as an allosteric activator.

Drug activation of AMPK

Maintaining energy balance is a fundamental property of every living organism. A key component in the regulation of cellular and whole-body energy homeostasis is the AMP-activated protein kinase (AMPK), which functions as a fuel sensor co-ordinating metabolic processes to balance nutrient supply with energy demand. AMPK is at the hub of metabolic control in response to diet and exercise and, for this reason, is considered one of the most important targets for new drugs to treat obesity, Type 2 diabetes and cardiovascular disease. Multiple AMPK activating drugs have been found but none have progressed to the Clinic and their mechanisms of activation are poorly understood. We have found that the AMPK activator A769662 is specific for AMPK heterotrimers that contain the b1 isoform and do not activate b2 containing heterotrimers. The structure of A769662 bound to the enzyme has been solved by the Camblin & Carling laboratories in the UK showing A769662 is positioned in a pocket between the b-subunit CBM domain and the small lobe of the a-subunit kinase. We have found that A769662 is capable of activating AMPK independent of upstream kinase phosphorylation of Thr172. A769662 dependent activation of AMPK is negligible but in the presence of AMP there is remarkable synergy leading to a 1,000-fold activation.  Our results raise the possibility of combining direct activating drugs with drugs that elevate AMP to exploit this synergy. A potential example is the widely used type 2 diabetes drug metformin, which increases cellular AMP with drugs like A769662.

Genetic modification of AMPK signaling pathways

AMPK phosphorylates and modulates key enzymes in all branches of metabolism, as well as transcription factors that regulate their expression, to reposition cellular metabolism away from anabolic, ATP-consuming pathways, to catabolic pathways. Given its pivotal role in cellular energy metabolism, the regulatory events surrounding AMPK activation are of great interest. In order to better understand AMPK’s physiological roles we have generated mice lacking either 1 or 2 subunits as well as mice containing Ala in place of the AMPK phosphorylation sites in some of its classical substrates, including acetyl-CoA carboxylase 1 and 2 and HMG-CoA reductase. b1 null mice are fertile and show no development phenotypes but have a 90% reduction in hepatic AMPK activity due to loss of the catalytic subunits. There is a modest reduction of AMPK activity in the hypothalamus and white adipose tissue and no change in skeletal muscle or heart. On a low fat or an obesity-inducing high fat diet, b1 null mice had reduced food intake, reduced adiposity, and reduced total body mass. Metabolic rate, physical activity, adipose tissue lipolysis, and lipogenesis were similar to wild type littermates. The reduced appetite and body mass of b1 null mice were associated with protection from high fat diet-induced hyperinsulinemia, hepatic steatosis, and insulin resistance. Thus loss of b1 reduces food intake and protects against the deleterious effects of an obesity-inducing diet. b2 KO mice are viable and breed normally but have reduced skeletal muscle AMPK α1 and α2 expression. During treadmill running β2 KO mice had reduced maximal and endurance exercise capacity, which was associated with lower muscle and heart AMPK activity and reduced levels of muscle and liver glycogen. Deletion of AMPK β2 reduces AMPK activity in skeletal muscle resulting in impaired exercise capacity and worsening of diet-induced obesity and glucose intolerance.  The combined b1b2 muscle specific double KO mice have a 96% reduction in exercise capacity highlighting the importance of AMPK in maintaining exercise capacity.

CaMKKβ and brain function

CaMKKβ belongs to the Ca2+ and calmodulin (CaM) dependent protein kinase (CaMK) subfamily and along with CaMKKα were initially identified as the upstream kinases responsible for phosphorylating and activating CaMK-IV and CaMK-I respectively. It is also an activating upstream kinase for the important metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) and the deacetylase Sirtuin 1 (Sirt1). Genetic loss of CaMKKβ leads to increased atherosclerotic lesions, as well as impaired long term memory formation. A mutation in human CaMKKβ (Thr85Ser) is associated with clinical anxiety, whereas a single nucleotide polymorphism (SNP; rs1063843) that causes decreased CaMKKβ expression is linked with schizophrenia. Consistent with these findings, we have found that mice lacking CaMKKβ exhibit anxiety and schizophrenic-like behaviour. We have shown that multisite phosphorylation of CaMKKβ is critical for regulating Ca2+/CaM dependence. We have identified an autophosphorylation site (Thr85) that is required for sustaining CaMKKβ activity after Ca2+ withdrawal. Autophosphorylation of the Thr85Ser mutant causes a sustained inhibition of CaMKKβ after Ca2+ withdrawal.

Student Projects


Publication Highlights

  1. Scott JW, Ling NXY, Issa SMA, Dite TA, O’Brien MT, Chen ZP, Galic S, Langendorf CG, Steinberg GR, Kemp BE, and Oakhill JS.  Drugs and AMP unite to switch on naive AMPK.  Chemistry and Biology.  2014, May 22;21(5):619-27.
  2. Fullerton MD, Galic S., Marcinko K, Pulinilkunnil T, Chen Z-P, O’Neill HM, Ford FJ, Palanivel R, O’Brien M., Hardie DG, Macaulay SL, Schertzer JD, Dyck JRB, van Denderen BJ, Kemp BE and Steinberg GR. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nature Medicine. 2013 Dec;19(12):1649-54.
  3. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012 May 18;336(6083):918-22.
  4. Oakhill JS, Scott JW, Kemp BE. AMPK functions as an adenylate charge-regulated protein kinase. Trends Endocrinol Metab. 2012 Mar;23(3):125-32.
  5. Galic S, Fullerton MD, Schertzer JD, Sikkema S, Marcinko K, Walkley CR, IzonD, Honeyman J, Chen ZP, van Denderen BJ, Kemp BE, Steinberg GR. Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest. 2011 Dec;121(12):4903-15.
  6. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S, Kemp BE. AMPK is a direct adenylate charge-regulated protein kinase. Science. 2011 Jun 17;332 (6036):1433-5.
  7. Oakhill JS, Chen ZP, Scott JW, Steel R, Castelli LA, Ling N, Macaulay SL, Kemp BE. β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19237-41. PubMed.
  8. Steinberg GR, Kemp BE. AMPK in Health and Disease Physiol Rev. 2009 Jul; 89(3): 1025-78